1. 引言

Oalib

Open Access Library Journal

2333-9705 2333-9721

Scientific Research Publishing

10.4236/oalib.1113282

Oalib-141997

Articles

Biomedical Life Sciences, Business Economics, Chemistry Materials Science, Computer Science Communications, Earth Environmental Sciences, Engineering, Medicine Healthcare, Physics Mathematics, Social Sciences Humanities

Lithium and Mental Health: The Small Element with a Big Impact

Isabela Dias

Cruvinel

¹ Tamara Rodrigues Lima

Zanuzzi

¹ Fábio Morato de

Oliveira

aResearch Center for Mental Health&Behavioral Genetics, Federal University of Jataí, Jataí-GO, Brazil

aHuman and Medical Genetics and Coordinator of the Research Center for Mental Health&Behavioral Genetics, Federal University of Jataí, Jataí-GO, Brazil

02 04 2025

12 04 1 17 17, March 2025 14, March 2025 14, April 2025

2014

This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

Lithium has long been established as a first-line mood stabilizer in the treatment of bipolar disorder and treatment-resistant depression. In addition to its psychiatric applications, lithium has demonstrated neuroprotective properties through its influence on neurotransmitter regulation, neuroplasticity, inflammation, and oxidative stress. Objective: This narrative review aims to provide a comprehensive analysis of lithium’s role in mental health, focusing on its clinical efficacy, underlying neurobiological mechanisms, and expanding therapeutic applications. The review also addresses safety considerations and explores innovative strategies to optimize lithium use in contemporary psychiatry. Methods: A systematic literature search was conducted in PubMed (MEDLINE) and the Virtual Health Library (BVS), covering publications from January 2000 to December 2024. Inclusion criteria comprised peer-reviewed original studies, systematic reviews, meta-analyses, and randomized clinical trials published in English, Portuguese, or Spanish. A total of 68 articles were selected following title and abstract screening and full-text analysis. These articles explored lithium’s clinical effects, mechanisms of action, safety profile, and emerging applications. Results: Lithium remains the gold standard for managing bipolar disorder, with strong evidence supporting its efficacy in mood stabilization and suicide prevention. Emerging data also support its use in major depressive disorder, schizoaffective disorder, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. However, its narrow therapeutic index necessitates close monitoring due to risks of renal, thyroid, and metabolic dysfunction. Recent advances in pharmacogenomics, sustained-release delivery systems, and microdosing approaches offer new avenues to enhance therapeutic efficacy while reducing adverse effects. Conclusion: Lithium continues to play a pivotal role in psychiatric treatment and is gaining relevance in neuroprotective strategies. Future research should prioritize the identification of predictive biomarkers, refinement of dosing strategies, and the development of personalized approaches to maximize benefits and ensure safe, long-term use.Subject AreasMental Health, Psychopharmacology, Neuroscience, Psychiatry

Lithium Mental Health Bipolar Disorder Neuroprotection Depressive Disorder

1. 引言近年来，随着多媒体技术和经济多元全球化的不断发展，跨界思维不断冲击着传统的品牌联合，电商、餐饮、服装等行业相继掀起跨界联合风潮，营销学之父菲利普·科特勒曾经说过：除了主流品牌和小众品牌以外，混合品牌也将在未来占据一席之地，其中这个混合品牌与后面的“跨界品牌联合”在某种程度上是一样的，跨界品牌联合是指处于不同行业边界的品牌跨边界进行合作共同推出新产品 [1] 。在跨界联合的实践过程中有的品牌跨界备受关注，溢出效应明显，例如Rio华为手机结合保时捷设计出的超级旗舰MateRS设计好评如潮，大白兔品牌奶糖与加美净这类日化品牌推出的奶糖味的唇膏，上架即一扫而光，然而有的跨界联合却反响平平，甚至出现负面溢出效果，例如喜茶与杜蕾斯的联合产品没有得到消费者的积极评价，甚至使消费者产生反感情绪。之前关于品牌联合效果影响因素的分析上主要体现在联合匹配性、在产品关系和逻辑上的契合度，以及品牌要素互补性方面，但是在研究跨界联合时没有考虑到跨界品牌双方本身就具有较大的差异性，所以在一定程度上对跨界联合的成败现象并不能完全解释。因此，本文聚焦品牌跨界联合情景下，根据形式与功能的整合程度将品牌跨界联合的整合度分为高、低两种，基于SOR模型 [2] ，进而分析品牌跨界联合时的整合度高低对消费者品牌联合评价的影响机制，并且在这个基础上研究消费者感知价值在品牌跨界联合时的整合度对消费者品牌联合评价的中介作用。 2. 文献回顾及研究假设(一) 品牌跨界联合整合度与消费者品牌联合评价相关研究有关品牌跨界联合的概念大多围绕跨界营销进行，在市场营销中有共生营销的概念，它是指一种合作联盟关系，合作双方及多方为实现资源共享，提升竞争能力而形成的一种长期或者短期联盟合作关系，而品牌跨界联合则是指两个异质行业、互相独立但拥有平等商业地位的品牌通过活化老品牌，共享互补资源，降低成本等方式以推出新产品，从而实现销售额的增加 [3] 。两者具有一定的相似性，因此根据前人的论述及本文的研究内容将品牌跨界联合大致定义为品牌联合的特殊形式，是指同一个新的产品中存有两个来自不同且没有竞争关系行业的品牌。由于合作品牌双方的合作程度对消费者的品牌评价会产生相应的影响，Newmeyer等(2018) [4] 根据联合产品在形式和功能上的结合程度提出了六种整合度不同的品牌联合形式，从低到高依次为同地品牌联合、共同促销、捆绑联合、成分联合、要素联合、共同研发联合，本文根据形式和功能的结合程度，将共同研发联合和元素联合划分为高度整合，成分联合和捆绑联合划分为中度整合，共同促销和同地品牌联合划分为低度整合。一个品牌产品所带来的功能或者形式较为单一，不能满足消费者日益多元的功能需求和价值需求，如果将两个异质性产品进行跨界联合，不仅能够带来冲击固有认知的创新感，还有益于提升消费者的忠诚度，但是差异过大的品牌联合可能会产生负面溢出效应 [5] 。所以大多学者聚焦于品牌跨界联合前的联合匹配性和契合度的研究，忽视了品牌跨界联合过程中的整合程度，而消费者对跨界品牌联合的评价在一定层面上反映出跨界联合双方合作的效果，较高的评价不仅有助于维持对品牌资产较好品牌的忠诚度，还有利于提升品牌资产较弱一方的品牌形象(Lin, 2013)，在跨界品牌联合中合作双方的交融程度越深，即产品整合度越高，越有益于消费者体验到品牌双方各自的优势，感受到跨界联合产品所带来的新奇与价值感，从而促进消费者对跨界品牌联合作出积极评价。综上所述，本文提出假设1：H1：在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。(二) 在品牌跨界联合时，感知价值在产品联合整合度对品牌联合评价中的中介作用消费者感知价值这一概念是基于现代营销中的消费者价值理论，该理论认为营销其实是交换价值与感知价值的过程，消费者在得到产品后会对其付出成本与感知价值效用进行比较，从而给出整体评价 [6] 。消费者感知价值时往往有三个特征，对产品价值会根据自身主观性进行感知，并且倾向于在比较中感知价值，其感知的价值还具有阶梯性 [7] 。因此，范秀成等(2003) [8] 将消费者感知价值概述为消费者对企业提供的产品和服务价值的主观评价，当消费者感知到价值时会对品牌联合产生积极评价，而产品整合度越高，即跨界联合产品无论是形式还是功能方面都高度融合，没有令消费者产生突兀感，能够驱动消费者产生价值感知，将异质的产品进行创新融合，起初的不匹配性能够打破了对原有品牌的刻板印象，再通过后面的高度整合能够使消费者产生创新感知的同时降低跨界创新产品的不确定性，感受到品牌联合带来的综合价值，而消费者的感知价值会影响消费者对品牌的选择，进而促进消费者对品牌联合作出正向评价 [9] 。因此，本文假设在品牌跨界联合过程中，合作双方后期在形式和功能上的产品整合度将影响消费者感知价值，又因为高整合度与品牌联合评价具有正向影响，推测消费者感知价值也将正向影响品牌联合评价。综上所述，本文提出假设2：H2：在品牌跨界联合时，消费者感知价值在产品整合度对消费者品牌联合评价的影响中起到中介作用。基于此，本文以SOR模型为研究框架，将品牌框架联合时的产品整合度作为刺激源，消费者从中获得的价值感知作为个体心理呈现，消费者对品牌联合的评价作为消费者者反应，构建在品牌跨界联合中产品整合程度对品牌联合评价的影响模型，模型如图1 所示。 Figure 1 <xref ref-type="bibr" rid="oalib.141997-"></xref>Figure 1. Research model图1. 研究模型图1. 研究模型 3. 实证设计与研究发现1) 研究设计与数据收集这部分由前测和正式实验组成，前测主要是通过了解市场上影响较广的跨界联合产品，并由此确定实验对象，正式实验根据产品组合利用单因素两水平，即产品整合程度高低的组间设计，检验品牌跨界联合时产品整合程度对品牌联合评价的主要影响以及消费者价值感知对其中的中介效应。① 前测。通过网络咨询了解与品牌跨界词条有关的内容，其中包含了有关跨界产品组合功能与形式的324条记录。选择了6组市面上真实的跨界组合案例，分别为蔻驰皮革的贝克家具、加入当尼柔顺剂的汰渍洗衣液、安装劳斯莱斯发动机的空客机、戴尔电脑与佳能打印机、配有迪士尼玩具的儿童餐、出售赛百味三明治的沃尔玛。通过变动产品整合度的操纵方法，让受访者填写整合度的7级量表 [4] ，对这些组合的产品整合度进行打分。此次前测收回有效问卷78份，并通过统计数据分析得出，蔻驰皮革的贝克家具这组共同研发组合的整合度评分均值为M _整合度 = 5.26，出售赛百味三明治的沃尔玛这组同地品牌联合销售的整合度评分均值为M _整合度 = 4.14，两者之间的差异很明显，将蔻驰皮革的贝克家具作为高整合度组合，而将出售赛百味三明治的沃尔玛作为低整合度组合，并将两组组合作为实验的刺激源。② 正式实验。该实验采用单因素两水平的设计，包括了102名消费者，其中人员年龄集中于26~35岁，男性占比42.15%，女性占比57.85%，教育程度占比主要是本科学历，将被试进行随机等量分配，其中高低整合度组各自均为61人。让产品高整合度组的被试浏览蔻驰皮革的贝克家具在功能和形式上的整合材料信息，同时让产品低整合度组的被试浏览沃尔玛出售赛百味三明治的销售整合信息，两组被试在看到品牌跨界联合刺激材料后如实填写产品感知价值量表以及品牌联合评价量表，具体量表题项如表1 所示。 Table 1 <xref ref-type="bibr" rid="oalib.141997-"></xref>Table 1. Measurement scaleTable 1. Measurement scale 表1. 测量量表

测量维度	测量题项参考来源
消费者感知价值	讨论/拥有/分享这项联名让我很开心	李慧，周雨(2021)
	讨论/拥有/分享这项联名让我给他人留下了好印象
	这项联名让我获得了自我满足	Sweeney and Soutar (2001)
	该联名是我喜欢的
	讨论/拥有/分享这项联名让我结识了很多朋友
品牌联合评价	我认为该产品很吸引人	Shih等(2013)
	我非常喜欢该联合产品
	该联合产品表达了我的个性

2) 数据分析① 问卷的信效度检验。利用SPSS 24.0对实验中的数据进行信度与效度的检验，其中产品感知价值量表以及品牌联合评价量表的Cronbach’ α系数分别为0.891、0.912，两者均在0.8以上，说明问卷信度较好。同时，通过验证性因子分析得出组合的CR和AVE值，从中发现组合效度AR值大于0.7，说明所选题项的一致性好，AVE值也达到了推荐的标准，所以该变量具有较好的效度。②主效应检验。在品牌跨界联合中，通过独立样本T检验验证产品整合度对消费者品牌联合评价有显著影响，即主效应检验。如表2 所示，产品整合度不同，消费者对品牌跨界联合评价也显著不同，在产品整合度较高的跨界联合中，消费者对品牌联合评价(M = 2.811)显著高于产品整合度低的跨界联合产品(M = 1.649)，因此本文的假设1得到验证，即在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。 Table 2 <xref ref-type="bibr" rid="oalib.141997-"></xref>Table 2. Comparison of consumers’ evaluation of co-brand under different product integration degreesTable 2. Comparison of consumers’ evaluation of co-brand under different product integration degrees 表2. 不同产品整合度下消费者对品牌联合评价的差异比较

	整合度分组	个案数	平均值	标准差	T值
品牌联合评价	高整合度	61	2.811	0.678	−5.650^***
品牌联合评价	低整合度	61	1.649	0.718	−5.650^***

③ 中介效应检验。本文以跨界产品整合度为自变量、消费者感知价值为中介变量、品牌联合评价为因变量，运用PROCESS程序中的model 4，通过Bootstrap方法对感知价值的中介效应进行检验，其中控制性别、年龄等人口特征变量。结果显示，产品整合程度对品牌联合评价的总效应为0.942，95%置信区间为(0.642, 1.193)，直接效应为0.401，95%置信区间为(0.076, 0.723)，均不包括0，产品整合程度对消费者感知价值具有显著的正向影响[B = 1.231, 95%置信区间为(0.844, 1.713), SE = 0.231, t = 5.895, p < 0.01]，消费者感知价值对品牌联合评价具有显著正向影响[B = 0.449, 95%置信区间为(0.289, 0.589), SE = 0.071, t = 6.334, p < 0.01]，从产品整合度到感知价值，再到品牌联合评价，其中的间接效应为0.673，95%的置信区间(0.302, 0.937)，不含0，由此得以验证感知价值在产品整合程度与品牌联合评价关系里起到中介作用。 4. 结论与启示本文通过实证分析研究了处于品牌跨界联合中，产品整合度对品牌联合评价的影响关系，主要得到两个结论：首先，在品牌跨界联合时，相比于产品整合度较低的跨界组合，产品整合度高的跨界组合更能够带来积极的品牌联合评价，即产品整合度对品牌联合评价有正向影响；其次，消费者感知价值在跨界产品整合度对品牌联合评价的影响中起到中介作用。通过实证研究，发现产品整合度越高，越有利于消费者感知价值，同时当消费者感知价值以后会对品牌联合作出积极评价，即消费者感知价值在跨界产品整合度和品牌联合评价中起到中介作用。而SOR理论正是关于刺激对个体心理产生影响，从而产生反应的研究模型，因此本文基于SOR理论，在品牌跨界联合时，产品整合度高这一刺激源使得消费者根据偏好流畅性的心理会降低对跨界创新产品的不确定性，从而增强消费者对该类商品的接受度，并从中感知到联合的综合价值。当消费者感受到情绪价值或者社会价值时会产生积极反应，即较高的品牌联合评价，这不仅维持了消费者对原有品牌产品的忠诚度，又在一定程度上提升了品牌资产，为企业有针对性地进行品牌跨界联合提供了感知价值角度的理论支持。本文的研究为企业进行跨界创新实践活动提供了相应指导。首先，尽管市场上出现的跨界创新现象层出不穷，与不同的品牌进行跨界创新能够在短期内快速吸引消费者，并从长期唤起品牌活力，提升品牌创新能力，但是在这个过程中企业应该结合自身的发展情况和战略模式进行调整，不要跟风进行盲目跨界。合适的跨界能够带来正面效应，但是如果缺少跨界的前提情景和适宜时机，跨界将给企业的发展带来无论是品牌形象还是消费者受众都产生消极影响。其次，在品牌跨界联合时，除了考虑前期匹配性，还需要进行整合度的规划。许多企业在进行品牌联合时往往考虑合作双方固有的形象或者市场是否匹配，匹配性较大可以提升消费者的可接受度，但是也可能固化消费者认知。对于需要进行品牌跨界转型的企业来说，同质品牌联合对于公司的发展战略来说意义不大，如果品牌联合异质性较大，品牌联合发行起初可能会吸引眼球，赚取热度，收获许多受众；对于品牌资产不对等的双方来说，影响也不尽相同，但后期消费者感知的功能和形式方面的异质性过于突出，可能会引起消费者的排斥心理，进而降低消费者评价。企业可以通过提升联合产品在功能和形式方面的交融整合度，产品整合度高时消费者更加容易理解品牌联合的意义和价值，也能够避免品牌联合带来的不适感，降低消费者对冲击固有认知的排斥，进而更加理解品牌融合的真正目的以及给自身带来的价值，有利于提升消费者对品牌联合的认同感，对品牌联合做出积极评价，将不匹配产品转换为一次具有创新意义的匹配产品。最后，如果将跨界产品匹配性作为消费者是否接受的前提条件，那么整合度的提升将有益于消费者从中感受到该跨界联合所带来的综合价值。好的品牌联合除了考虑前期双方的联合匹配度，也要形成良好的产品整合度，如果前期的匹配度不能达到预期，那么可以通过后期从产品和功能方面对匹配联合整合度进行调整，从而激发消费者的购买意愿以及对该品牌联合的积极评价。所以企业在实践中要注意消费者感知价值在产品整合度对品牌联合评价中的中介作用，通过良好的整合促使消费者感知产品价值，进而提升品牌联合评价。

References 1

Shorter, E. (2009) Before Prozac: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press.

Malhi, G.S. and Tanious, M. (2011) Optimal Frequency of Lithium Administration in the Treatment of Bipolar Disorder: Clinical and Dosing Considerations. CNS Drugs, 25, 289-298. >https://doi.org/10.2165/11586970-000000000-00000

World Health Organization (2019) WHO Model List of Essential Medicines. World Health Organization. >https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06

Rybakowski, J.K. (2018) Challenging the Negative Perception of Lithium and Optimizing Its Long-Term Administration. Frontiers in Molecular Neuroscience, 11, Article 349. >https://doi.org/10.3389/fnmol.2018.00349

Cipriani, A., Hawton, K., Stockton, S. and Geddes, J.R. (2013) Lithium in the Prevention of Suicide in Mood Disorders: Updated Systematic Review and Meta-Analysis. BMJ, 346, f3646. >https://doi.org/10.1136/bmj.f3646

Baldessarini, R. J., Tondo, L. and Hennen, J. (2003) Lithium Treatment and Suicide Risk in Major Affective Disorders: Update and New Findings. The Journal of Clinical Psychiatry, 64, 44-52. >https://pubmed.ncbi.nlm.nih.gov/12720484/

Marmol, F. (2008) Lithium: Bipolar Disorder and Neurodegenerative Diseases Possible Cellular Mechanisms of the Therapeutic Effects of Lithium. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1761-1771. >https://doi.org/10.1016/j.pnpbp.2008.08.012

Manji, H.K., Moore, G.J., Rajkowska, G. and Chen, G. (2000) Neuroplasticity and Cellular Resilience in Mood Disorders. Molecular Psychiatry, 5, 578-593. >https://doi.org/10.1038/sj.mp.4000811

Ishii, N., Terao, T., Araki, Y., Kohno, K., Mizokami, Y., Shiotsuki, I., et al. (2015) Low Risk of Male Suicide and Lithium in Drinking Water. The Journal of Clinical Psychiatry, 76, 319-326. >https://doi.org/10.4088/jcp.14m09218

Schrauzer, G.N. (2002) Lithium: Occurrence, Dietary Intakes, Nutritional Essentiality. Journal of the American College of Nutrition, 21, 14-21. >https://doi.org/10.1080/07315724.2002.10719188

McKnight, R.F., Adida, M., Budge, K., Stockton, S., Goodwin, G.M. and Geddes, J.R. (2012) Lithium Toxicity Profile: A Systematic Review and Meta-Analysis. The Lancet, 379, 721-728. >https://doi.org/10.1016/s0140-6736(11)61516-x

Malhi, G.S., Tanious, M., Das, P., Coulston, C.M. and Berk, M. (2013) Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs, 27, 135-153. >https://doi.org/10.1007/s40263-013-0039-0

Fountoulakis, K.N., Tohen, M. and Zarate, C.A. (2022) Lithium Treatment of Bipolar Disorder in Adults: A Systematic Review of Randomized Trials and Meta-Analyses. European Neuropsychopharmacology, 54, 100-115. >https://doi.org/10.1016/j.euroneuro.2021.10.003

Licht, R.W. (2011) Lithium: Still a Major Option in the Management of Bipolar Disorder. CNS Neuroscience & Therapeutics, 18, 219-226. >https://doi.org/10.1111/j.1755-5949.2011.00260.x

Diniz, B.S., Machado-Vieira, R. and Forlenza, O.V. (2013) Lithium and Neuroprotection: Translational Evidence and Implications for the Treatment of Neuropsychiatric Disorders. Neuropsychiatric Disease and Treatment, 9, 493-500. >https://doi.org/10.2147/NDT.S33086

Jope, R.S. (1999) Anti-Bipolar Therapy: Mechanism of Action of Lithium. Molecular Psychiatry, 4, 117-128. >https://doi.org/10.1038/sj.mp.4000494

Rowe, M.K. and Chuang, D. (2004) Lithium Neuroprotection: Molecular Mechanisms and Clinical Implications. Expert Reviews in Molecular Medicine, 6, 1-18. >https://doi.org/10.1017/s1462399404008385

Nonaka, S., Hough, C.J. and Chuang, D. (1998) Chronic Lithium Treatment Robustly Protects Neurons in the Central Nervous System against Excitotoxicity by Inhibiting N-Methyl-D-Aspartate Receptor-Mediated Calcium Influx. Proceedings of the National Academy of Sciences, 95, 2642-2647. >https://doi.org/10.1073/pnas.95.5.2642

Liang, M.H. and Chuang, D.M. (2007) GSK-3 as a Target for Lithium-Induced Neuroprotection against Excitotoxicity in Primary Cultures of Rat Cerebral Cortex Neurons. Frontiers in Molecular Neuroscience, 4, Article 15.

Chalecka-Franaszek, E. and Chuang, D. (1999) Lithium Activates the Serine/Threonine Kinase Akt-1 and Suppresses Glutamate-Induced Inhibition of Akt-1 Activity in Neurons. Proceedings of the National Academy of Sciences, 96, 8745-8750. >https://doi.org/10.1073/pnas.96.15.8745

Gideons, E.S., Lin, P., Mahgoub, M., Kavalali, E.T. and Monteggia, L.M. (2017) Chronic Lithium Treatment Elicits Its Antimanic Effects via BDNF-TrkB Dependent Synaptic Downscaling. eLife, 6, [page]. >https://doi.org/10.7554/elife.25480

Ghanaatfar, F., Ghanaatfar, A., Isapour, P., Farokhi, N., Bozorgniahosseini, S., Javadi, M., et al. (2022) Is Lithium Neuroprotective? An Updated Mechanistic Illustrated Review. Fundamental & Clinical Pharmacology, 37, 4-30. >https://doi.org/10.1111/fcp.12826

Singulani, M.P., De Paula, V.J.R. and Forlenza, O.V. (2021) Mini Review: Mitochondrial Dysfunction in Alzheimer’s Disease: Therapeutic Implications of Lithium. Neuroscience Letters, 760, Article 136078. >https://doi.org/10.1016/j.neulet.2021.136078

Fabbri, C. (2020) The Role of Genetics in Bipolar Disorder. In: Young, A.H. and Juruena, M.F., Eds., Bipolar Disorder: From Neuroscience to Treatment, Springer International Publishing, 41-60. >https://doi.org/10.1007/7854_2020_153

López-Muñoz, F., Shen, W.W., D’Ocon, P., Romero, A. and Álamo, C. (2018) A History of the Pharmacological Treatment of Bipolar Disorder. International Journal of Molecular Sciences, 19, Article 2143. >https://doi.org/10.3390/ijms19072143

Airainer, M. and Seifert, R. (2024) Lithium, the Gold Standard Drug for Bipolar Disorder: Analysis of Current Clinical Studies. Naunyn-Schmiedeberg's Archives of Pharmacology, 397, 9723-9743. >https://doi.org/10.1007/s00210-024-03210-8

Bowden, C.L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., et al. (2005) A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder. The Journal of Clinical Psychiatry, 66, 111-121. >https://doi.org/10.4088/jcp.v66n0116

Keck, P.E., Orsulak, P.J., Cutler, A.J., Sanchez, R., Torbeyns, A., Marcus, R.N., et al. (2009) Aripiprazole Monotherapy in the Treatment of Acute Bipolar I Mania: A Randomized, Double-Blind, Placebo-and Lithium-Controlled Study. Journal of Affective Disorders, 112, 36-49. >https://doi.org/10.1016/j.jad.2008.05.014

Young, A.H., Calabrese, J.R., Gustafsson, U., Berk, M., McElroy, S.L., Thase, M.E., et al. (2013) Quetiapine Monotherapy in Bipolar II Depression: Combined Data from Four Large, Randomized Studies. International Journal of Bipolar Disorders, 1, Article No. 10. >https://doi.org/10.1186/2194-7511-1-10

Tohen, M., Vieta, E., Calabrese, J., Ketter, T.A., Sachs, G., Bowden, C., et al. (2003) Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 60, 1079-1088. >https://doi.org/10.1001/archpsyc.60.11.1079

Bowden, C.L. Calabrese, J.R., McElroy, S.L., Gyulai, L., Wassef, A., Petty, F., et al. (2000) A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients with Bipolar I Disorder. Archives of General Psychiatry, 57, 481-489. >https://doi.org/10.1001/archpsyc.57.5.481

Calabrese, J.R., Bowden, C.L., Sachs, G., Yatham, L.N., Behnke, K., Mehtonen, O., et al. (2003) A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder. The Journal of Clinical Psychiatry, 64, 1013-1024. >https://doi.org/10.4088/jcp.v64n0906

Weisler, R.H., Nolen, W.A., Neijber, A., Hellqvist, Å. and Paulsson, B. (2011) Continuation of Quetiapine versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder(Trial 144: A Randomized Controlled Study). The Journal of Clinical Psychiatry, 72, 1452-1464. >https://doi.org/10.4088/jcp.11m06878

Baldessarini, R.J., Tondo, L., Davis, P., Pompili, M., Goodwin, F.K. and Hennen, J. (2006) Decreased Risk of Suicides and Attempts during Long‐Term Lithium Treatment: A Meta‐Analytic Review. Bipolar Disorders, 8, 625-639. >https://doi.org/10.1111/j.1399-5618.2006.00344.x

Baldessarini, R.J., Tondo, L. and Hennen, J. (1999) Effects of Lithium Treatment and Its Discontinuation on Suicidal Behavior in Bipolar Manic-Depressive Disorders. The Journal of Clinical Psychiatry, 60, 77-116.

Fiorillo, A., Sampogna, G., Albert, U., Maina, G., Perugi, G., Pompili, M., et al. (2023) Facts and Myths about the Use of Lithium for Bipolar Disorder in Routine Clinical Practice: An Expert Consensus Paper. Annals of General Psychiatry, 22, Article No. 50. >https://doi.org/10.1186/s12991-023-00481-y

Müller-Oerlinghausen, B., Felber, W., Berghöfer, A., Lauterbach, E. and Ahrens, B. (2005) The Impact of Lithium Long-Term Medication on Suicidal Behavior and Mortality of Bipolar Patients. Archives of Suicide Research, 9, 307-319. >https://doi.org/10.1080/13811110590929550

Cipriani, A., Pretty, H., Hawton, K. and Geddes, J.R. (2005) Lithium in the Prevention of Suicidal Behavior and All-Cause Mortality in Patients with Mood Disorders: A Systematic Review of Randomized Trials. American Journal of Psychiatry, 162, 1805-1819. >https://doi.org/10.1176/appi.ajp.162.10.1805

Leucht, S., Helfer, B., Dold, M., Kissling, W. and McGrath, J.J. (2015) Lithium for Schizophrenia. Cochrane Database of Systematic Reviews, No. 10, CD003834. >https://doi.org/10.1002/14651858.cd003834.pub3

Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Bond, D.J., Frey, B.N., et al. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 Guidelines for the Management of Patients with Bipolar Disorder. Bipolar Disorders, 20, 97-170. >https://doi.org/10.1111/bdi.12609

Vallée, A., Vallée, J. and Lecarpentier, Y. (2021) Lithium and Atypical Antipsychotics: The Possible Wnt/β Pathway Target in Glaucoma. Biomedicines, 9, Article 473. >https://doi.org/10.3390/biomedicines9050473

Can, A., Schulze, T.G. and Gould, T.D. (2014) Molecular Actions and Clinical Pharmacogenetics of Lithium Therapy. Pharmacology Biochemistry and Behavior, 123, 3-16. >https://doi.org/10.1016/j.pbb.2014.02.004

Muneer, A. (2020) Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder and Implications for COVID-19 Infection. International Journal of Molecular Sciences, 21, Article 7740.

Schweizer, E., Rickels, K., Weiss, S. and Zavodnick, S. (1993) Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine. Archives of General Psychiatry, 50, 51-60. >https://doi.org/10.1001/archpsyc.1993.01820130053009

Schaffer, L.C. and Schaffer, C.B. (2005) Use of Lithium in the Treatment of Anxiety Disorders: A Case Series. Primary Care Companion to the Journal of Clinical Psychiatry, 7, 282-285.

Young, L.T. (2004) The Neurobiology of Bipolar Disorder: Focus on BDNF and Stress. Current Drug Targets-CNS&Neurological Disorders, 3, 143-149.

Halaris, A. and Plietz, J. (2007) Agonistic and Antagonistic Effects of Lithium on Serotonin Function in the CNS. Neuropsychobiology, 55, 1-11.

O’Brien, W.T., Harper, A.D., Jové, F., Woodgett, J.R., Maretto, S., Piccolo, S., et al. (2004) Glycogen Synthase Kinase-3β Haploinsufficiency Mimics the Behavioral and Molecular Effects of Lithium. The Journal of Neuroscience, 24, 6791-6798. >https://doi.org/10.1523/jneurosci.4753-03.2004

Shine, B., McKnight, R.F., Leaver, L. and Geddes, J.R. (2015) Long-Term Effects of Lithium on Renal, Thyroid, and Parathyroid Function: A Retrospective Analysis of Laboratory Data. The Lancet, 386, 461-468. >https://doi.org/10.1016/s0140-6736(14)61842-0

Bocchetta, A., Ardau, R., Fanni, T., Sardu, C., Piras, D., Pani, A., et al. (2015) Renal Function during Long-Term Lithium Treatment: A Cross-Sectional and Longitudinal Study. BMC Medicine, 13, Article No. 12. >https://doi.org/10.1186/s12916-014-0249-4

Lazarus, J.H. (2009) Lithium and Thyroid. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 723-733. >https://doi.org/10.1016/j.beem.2009.06.002

Mak, T.W., Shek, C.C., Chow, C.C., Wing, Y.K. and Lee, S. (1993) Effects of Lithium Therapy on Parathyroid and Calcium Metabolism. Archives of Internal Medicine, 153, 439-443.

Rybakowski, J.K., Permoda-Osip, A. and Bartkowska-Sniatkowska, A. (2012) Structural Brain Imaging in Lithium-Treated and Lithium-Naive Patients with Bipolar Disorder. Pharmacopsychiatry, 45, 147-153.

Goodwin, F.K. and Jamison, K.R. (2007) Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2rd Edition, Oxford University Press.

Gray, J.D. and McEwen, B.S. (2013) Lithium’s Role in Neural Plasticity and Its Implications for Mood Disorders. Acta Psychiatrica Scandinavica, 128, 347-361. >https://doi.org/10.1111/acps.12139

Chiu, C.T. and Chuang, D.M. (2010) Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Neuroprotection. Frontiers in Molecular Neuroscience, 3, Article 15.

Nabi, Z., Stansfeld, J., Plöderl, M., Wood, L. and Moncrieff, J. (2022) Effects of Lithium on Suicide and Suicidal Behaviour: A Systematic Review and Meta-Analysis of Randomised Trials. Epidemiology and Psychiatric Sciences, 31, e65. >https://doi.org/10.1017/s204579602200049x

Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., et al. (2011) Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania: A Multiple-Treatments Meta-Analysis. The Lancet, 378, 1306-1315. >https://doi.org/10.1016/s0140-6736(11)60873-8

The BALANCE Investigators and Collaborators (2010) Lithium Plus Valproate Combination Therapy versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE): A Randomised Open-Label Trial. The Lancet, 375, 385-395. >https://doi.org/10.1016/S0140-6736(09)61828-6

Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., et al. (2005) Long-Term Response to Lithium Salts in Bipolar Illness Is Influenced by the Glycogen Synthase Kinase 3-β-50T/C SNP. Neuroscience Letters, 376, 51-55. >https://doi.org/10.1016/j.neulet.2004.11.022

Alda, M. (2015) Lithium in the Treatment of Bipolar Disorder: Pharmacology and Pharmacogenetics. Molecular Psychiatry, 20, 661-670. >https://doi.org/10.1038/mp.2015.4

Ferreira, M.A.R., O’Donovan, M.C., Meng, Y.A., Jones, I.R., Ruderfer, D.M., Jones, L., et al. (2008) Collaborative Genome-Wide Association Analysis Supports a Role for ANK3 and CACNA1C in Bipolar Disorder. Nature Genetics, 40, 1056-1058. >https://doi.org/10.1038/ng.209

Hou, L., Heilbronner, U., Degenhardt, F., Adli, M., Akiyama, K., Akula, N., et al. (2016) Genetic Variants Associated with Response to Lithium Treatment in Bipolar Disorder: A Genome-Wide Association Study. The Lancet, 387, 1085-1093. >https://doi.org/10.1016/S0140-6736(16)00143-4

International Consortium on Lithium Genetics (2018) Polygenic Dissection of Lithium-Responsive Bipolar Disorder. Molecular Psychiatry, 23, 582-590.

Squassina, A., Manchia, M., Congiu, D., Chillotti, C., Ardau, R. and Del Zompo, M. (2011) The Use of Gene Expression Microarrays and Whole Exome Sequencing in Lithium Pharmacogenomics. Frontiers in Psychiatry, 2, Article 71.

Song, J., Bergen, S.E., Di Florio, A., Karlsson, R., Charney, A.W., Ruderfer, D.M., et al. (2016) Genome-Wide Association Study Identifies SESTD1 as a Novel Risk Gene for Lithium-Responsive Bipolar Disorder. Molecular Psychiatry, 21, 1290-1297. >https://doi.org/10.1038/mp.2015.165